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Genomic medicine, in its broadest sense of being medical 
developments  informed  by  ‘omic’  advances,  has  con­
tinued to move towards the clinic in 2011. To mark the 
end of the year and the beginning of 2012, the editors of 
the six sections within Genome Medicine were invited to 
provide their highlights of the past year and to hint at the 
developments that we are likely to see in the near future.
Six different areas of progress are covered here, but the 
core of genomic medicine continues to be intrinsically 
linked  to  improvements  in  the  underlying  technology, 
and  two  obvious  examples  are  sequencing  and  mass 
spec  trometry.  Technological  advances  have  enabled 
larger  studies  and  more  complex  analyses,  allowing 
researchers and clinicians to track changes within a single 
cell and yet spot patterns across a whole population and 
within  an  entire  physiological  system.  The  foundations 
laid in 2011 should help the field to tackle the challenges 
of translating genomic medicine to the clinic in 2012.
Complex genomic rearrangements and disease
The past year has been marked by advances in the speed, 
accuracy and scale of genome sequencing. These improve­
ments  have  led  to  the  first  population­scale  genome 
sequencing  study  to  provide  information  on  structural 
variants [1]. Over 15,000 novel structural variants were 
identified  from  185  individuals.  Analysis  of  breakpoint 
junctions revealed that 70% of deletions and almost 90% 
of insertions showed microhomology ranging from 2 bp 
to 376 bp at the junctions. This suggests that nonhomolo­
gous  recombination  mechanisms  are  predominant  in 
copy number variation, and that microhomology­mediated 
DNA replication mechanisms, such as microhomology­
mediated break­induced replication, might have a major 
role in human genome structural variation.
Genome  sequencing  also  revealed  the  extent  of 
complex  genomic  rearrangements  (CGRs)  in  disease. 
Over 700 genomes from different cancers were studied, 
and ‘chromosome catastrophes’ were identified in 2 to 3% 
of all cancers and in up to 25% of bone cancers [2]. This 
phenomenon,  also  termed  ‘chromothripsis’  (shattering 
and regluing of chromosomes), is primarily localized to 
single  chromosomes,  but  includes  multiple  structural 
genomic changes, such as gains, losses and inversions. As 
a  result,  chromothripsis  can  lead  to  the  simultaneous 
occurrence of mutations in a number of different cancer­
causing genes. Cancer is known to be driven by somati­
cally  acquired  point  mutations  and  chromosomal  re­
arrangements,  conventionally  thought  to  accumulate 
gradually over time. However, chromothripsis is a one­off 
event resulting in multigenic changes [2]. It remains to be 
shown  whether  chromothripsis  is  a  major  driver  of 
cancer.
Intriguingly, a similar chromosome catastrophe event 
that resulted in CGRs was found to be associated with a 
small fraction of genomic disorders [3]. This involved a 
germline or constitutional rearrangement event early in 
embryogenesis  rather  than  somatically  acquired  muta­
tions and seemed to occur via a DNA­replication­based 
mechanism.  Triplicated  genomic  segments  were  also 
identified within the rearrangements, and micro  homology 
was  present  at  many  of  the  breakpoint  junctions.  The 
triplication cannot readily be explained by chromo  thrip­
sis, as it requires a gain of genetic information, probably 
resulting from DNA replication. Other CGRs identified 
in  association  with  genomic  disorders  included  tripli­
cations;  triplicated  dosage­sensitive  genes  conveyed  a 
more severe clinical phenotype than duplication. Tripli­
ca  tions seem to occur by a double crossover event within 
a  flanking  low­copy  repeat  and  are  tandem  in  nature, 
similar to earlier predictions from an unequal crossing­
over or non­allelic homologous recombination (NAHR) 
model [4]. However, many of the observed triplications 
have a complex ‘duplication­inverted triplication­duplica­
tion’  structure,  which  requires  only  two  breakpoint 
junctions. One of these is generated by an initial NAHR 
event between inverted repeats, and the other occurs by a 
nonhomologous mechanism, potentially a DNA replication­
based mechanism that results in microhomology at the 
breakpoint  junction  [5].  The  inversion  allows  distant 
genomic regions to be brought into spatial proximity.
A  summary  of  2011  would  not  be  complete  without 
highlighting  exome  sequencing  and  its  role  in  the 
elucidation  of  the  gene(s)  responsible  for  a  number  of  © 2010 BioMed Central Ltd
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© 2012 BioMed Central Ltddifferent Mendelian disorders [6]. Genomic studies have 
so far revealed the tremendous extent of rare variants in 
individual genomes. This has led to the concept of ‘clan 
genomics’  [7],  wherein  the  most  relevant  medically 
actionable variation may be rare variants that occurred as 
novel combinations or as new mutations in your personal 
genome or that of your nearest relatives.
James R Lupski, Section Editor,   
Molecular genetics, genomics & epigenetics of disease
Bringing quantification to the proteome
The ability to conduct global analysis of proteomes has 
existed for about a decade now. During this period most 
of the progress has been on increasing the number of 
proteins identified within the proteome. Because of the 
lack of inherent quantification within the data supplied 
by high­throughput mass spectrometry (MS), measuring 
the  absolute  concentration  of  proteins  across  the  pro­
teome has lagged behind. This situation is analogous to 
having a recipe in which the ingredients are listed but the 
amount of each required is not supplied. Without know­
ing how much of each ingredient to add, it is unlikely that 
the dish would taste very good.
Recent studies have moved to develop techniques to 
supply this vital piece of information. Selbach and colleagues 
[8] used a combination of stable isotope incorporation 
and MS to quantify pulse­labeled proteins and 4­thiouridine 
incorporation  to  quantify  newly  synthesized  RNA  in 
mouse  cells.  These  results  showed  that  genes  that 
respond quickly to stimuli (such as those encoding trans­
cription factors and signaling proteins) have short protein 
and  mRNA  half  lives.  Constitutive  processes  (such  as 
translation and central metabolism) were populated by 
genes giving rise to stable proteins and mRNA. A more 
recent study by Aebersold and colleagues [9] provided an 
absolute  quantitative  estimate  of  approximately  7,000 
proteins in a human cell line during exponential and M­
phase growth. This study also found that proteins related 
to  translation  were  found  in  high  abundance,  whereas 
those  involved  in  processes  such  as  transcription  and 
signaling  are  present  in  very  low  abundance.  These 
results are in agreement with those found by Selbach and 
colleagues  [8],  with  both  studies  suggesting  that  the 
correlation between mRNA and protein levels is greater 
than previously reported [10,11].
Although it is possible to measure the absolute number 
of specific proteins within complex mixtures [12], these 
studies  represent  a  new,  hopefully  broader,  effort  in 
determining the absolute abundances of proteins across 
an  entire  proteome.  Frankly,  without  this  quantitative 
information  it  is  impossible  to  accurately  understand 
cellular processes at a systems­level view.
Timothy Veenstra, Section Editor,   
Post-genomic advances in medicine
The human microbiome, our personal health and 
diseases
Microbial  cells  in  the  human  body  outnumber  human 
cells by two orders of magnitude. During the past decade, 
there has been growing interest in the analysis of these 
microbial communities, which are an integral part of the 
human body and provide us with nutrients essential to 
our health. With the rapid increase in sequencing power, 
the  characterization  of  the  so­called  ‘microbiome’  has 
given  rise  to  large  ‘metagenomic’  datasets,  revealing  a 
wealth  of  microbial  species  that  were  previously  un­
known and cannot be cultured.
The  gut  microbiome  is  the  most  extensively  studied 
part of the human microbiome so far, and this past year 
the international MetaHIT Consortium has consolidated 
the data to support the existence of a limited number of 
‘enterotypes’, stable clusters of bacterial communities that 
are common to groups of individuals belonging to differ­
ent  human  populations  rather  than  specific  for  each 
popu  lation [13,14]. Enterotypes are ‘well­balanced host­
microbial symbiotic states that might respond differently 
to diet and drug intake’ and warrant functional analysis 
to  complement  species  identification  obtained  through 
next­generation sequencing.
The  same  sequencing  approach  is  being  successfully 
extended to characterize the microbiome in other human 
tissues,  such  as  nasal  passages,  oral  cavities,  skin  and 
urogenital tract within the Human Microbiome Project 
[15,16].  Significant  challenges  remain  in  establishing 
robust and efficient bioinformatics pipelines to deal with 
the very large sequence datasets generated [17], but the 
integration  of  metagenomics  with  functional  genomics 
has started to provide new insights into the role of the 
microbiome in health and in disease susceptibility, diag­
nosis, progression and treatment, as reviewed extensively 
by Nicholson and colleagues in this journal [18]. Although 
emphasis  so  far  has  been  on  bacterial  communities, 
metagenomics  provide  simultaneous  access  to  fungi, 
protozoa and viruses, revealing that the vast majority had 
not  been  identified  through  classical  culture­based 
techniques. Functional metagenomics is thus opening a 
window  into  an  as­yet  largely  unexplored  biological 
world,  and  is  starting  to  fill  gaps  in  our  knowledge  of 
health and diseases. It is likely that microbiome studies 
will flourish in the coming years and will contribute to a 
more  personal  appraisal  of  our  medical  condition  and 
potential response to treatment.
Charles Auffray, Section Editor,   
Systems medicine and informatics
Progress in pharmacogenomics and individualized 
medicine
In the past year some very important contributions have 
been made indicating that genomic information predicts 
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promoting  the  concept  of  personalized  medicine  and 
pharmacogenomics. Although the integration of individ­
ual  ized  medicine  into  clinical  decision  making  is  still 
limited  [19],  there  is  increasing  evidence  for  genetic 
markers  for  major  drug­induced  hypersensitivity  reac­
tions  in  the  major  histocompatibility  complex  (MHC) 
region. Examples of such adverse reactions include the 
Steven­Johnson  syndrome  (SJS)  and  the  related  toxic 
epidermal necrolysis (TEN), with mortalities of 10% and 
30%, respectively.
Carbamazepine,  an  antiepileptic  drug  also  used  for 
treatment  of  other  conditions,  including  bipolar  dis­
orders,  and  for  pain  management  in  trigeminal 
neuralgia,  induces  different  manifestations  of  these 
hypersensitivity  reactions.  In  2004  the  HLA­B*1502 
allele  was  strongly  associated  with  SJS/TEN  in  Han 
Chinese people [20]. In a recent study, 4,855 Taiwanese 
were prospectively screened for the HLA­B*1502 allele 
before onset of carbamazepine treatment, and all HLA­
B*1502­positive people (7.7%) were offered alternative 
medications to carba  mazepine and did not develop SJS/
TEN [21]. Although the estimated historical incidence 
for SJS/TEN in Southeast Asians is 0.23%, no cases of 
SJS/TEN  were  identified  among  the  4,120  study 
participants treated with carbamazepine. This prospec­
tive study clearly indicates that genetic testing for HLA­
B*1502 seems to be warranted in clinical practice for 
the prevention of carbamazepine­associated SJS/TEN in 
Southeast Asians.
Recent data have suggested that different HLA alleles 
might  contribute  to  carbamazepine­related  hypersensi­
tivity reactions in patients with other ethnic backgrounds 
[22],  and  a  genome­wide  association  study  (GWAS) 
found a strong association for the HLA­A*3101 allele in 
22 people with Northern European ancestry and carba­
mazepine­induced hypersensitivity reactions, as compared 
with  2,691  healthy  controls  [23].  Whereas  the  HLA­
B*1502 allele seems to be a phenotype­specific predictor 
for the development of SJS/TEN in Asians, in Europeans 
the  HLA­A*3101  allele  seems  to  be  associated  with 
multiple  phenotypes  of  carbamazepine  hypersensitivity 
reactions,  including  SJS/TEN.  In  a  separate  GWAS, 
multiple  HLA  class  I  and  II  alleles  were  identified  as 
susceptibility  factors  for  idiosyncratic  amoxicillin­
clavulanate­induced liver injury, further supporting the 
importance of genetic variation in the MHC region in 
idiosyncratic adverse drug reactions [24].
In addition to the major efforts to individualize drug 
therapy using genomic information alone, metabolomics 
promises  significant  achievements  towards  a  better 
under  standing  of  the  potential  relevance  of  genetic 
variants in disease susceptibility as well as drug therapy, 
by the study of metabolism at the global level. A highlight 
in this field was the first analysis that comprehensively 
combined genomic information (from GWAS) with non­
targeted metabolic profiling of serum from subjects of 
two  independent  cohorts  (n  =  2,820)  for  hypothesis 
genera  tion [25]. Meta­analysis revealed 37 independent 
loci with genome­wide significance, providing not only 
new functional insights for disease susceptibility but also 
novel biochemical data for genotype­dependent reactions 
to drug therapy. This approach highlights the enormous 
potential  of  integrated  analyses  for  pharmacology  and 
clinical pharmacology in the near future.
Matthias Schwab, Section Editor,   
Personalized medicine & therapeutics
Beyond base pairs to bedside
In  February  2011,  more  than  10  years  after  a  draft 
sequence of the human genome was published, the US 
National Human Genome Research Institute announced 
its new strategic plan for genomic medicine from base 
pairs to bedside [26]. The plan calls for evaluating the 
structure  and  biology  of  genomes;  understanding  the 
biology  of  disease;  advancing  the  science  of  medicine; 
and  improving  the  effectiveness  of  healthcare.  Never­
theless, fulfilling the promise of genomics in improving 
health  requires  a  multidisciplinary  research  agenda 
beyond  bench  to  bedside,  an  agenda  that  will  demon­
strate  added  value  of  genome­based  information  for 
improving health in populations [27].
Currently, this translational research agenda is much 
less robust than discovery research, accounting for less 
than 2% of funded genomics research and research publi­
cations [28], but this is likely to change in the next decade 
as more and more applications make it to the bedside. 
Ongoing horizon scanning for genomic tests has revealed 
more than 330 genomic tests have reached the bedside 
since  2009  [29].  In  addition,  the  US  Food  and  Drug 
Administration has provided drug labeling information 
about adverse reactions for more than 80 gene­drug pairs 
[30].
With  rapid  improvements  in  technologies,  we  are 
seeing  the  leading  edge  of  the  applications  of  whole 
genome sequencing (WGS) in practice primarily in the 
identification of rare heritable conditions [31]. Deploying 
WGS in practice will require a systematic evidence­based 
approach to binning genes and gene variants into tiers 
based on levels of evidence for improving health; recently, 
Berg et al. [32] proposed a three­tier binning schema for 
WGS, based on the availability of information on their 
clinical  validity  and  utility.  The  ultimate  success  of 
genomics for improving health will require adoption of 
evidence­based approaches for their use in clinical and 
public health practice.
Muin Khoury, Section Editor,   
Genomic epidemiology & public health genomics
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As genomic technologies advance at an accelerating pace, 
direct­to­consumer (DTC) genetic testing has emerged 
as  a  dominant  area  of  ELSI  (ethical,  legal  and  social 
issues)  inquiry.  Indeed,  over  the  past  few  years,  DTC 
testing has received a tremendous amount of attention 
from policymakers, ELSI scholars and the popular press 
[33].  Although  it  remains  uncertain  whether  this 
industry, which is fueled by the availability of cheap and 
efficient  testing  technologies,  will  attract  a  broad 
consumer base [34], its growth has triggered a diverse 
array of regulatory responses, from outright bans [35] to 
recommendations that call for the provision of accurate 
information and valid results [36].
The DTC industry has also allowed ELSI researchers to 
explore popular culture representations of genetics [37], 
how individuals react to genetic risk information and the 
motivations behind the use of DTC services [38]. Much 
of  this  research  has  provided  surprising  results  ­ 
highlighting both problems (for example, the degree to 
which  the  benefits  and  limitations  of  testing  are  often 
misrepresented [39] and the reality that much provided 
risk information may be inaccurate [40]) and the fact that 
some concerns may not be as problematic as previously 
thought (for example, the degree to which people become 
anxious after receiving predisposition information [41]). 
Given  the  appearance  of  the  DTC  industry,  ELSI 
researchers  are  now  contemplating  future  policy  chal­
lenges.  For  example,  the  use  of  DTC  services  for  the 
testing  of  children  and  the  availability  of  cheap  WGS, 
which is inevitable in the near future, seem likely to add 
new and challenging dimensions to the DTC story.
Timothy Caulfield, Section Editor,   
Social, ethical & legal issues in genomic medicine
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